September 17, 2012 – Washington, DC – The not-for-profit Center for Lawful Access and Abuse Deterrence (CLAAD) today announced a national contest to identify the "Top 5 Technologies To Reduce Prescription Drug Abuse." The competition aims to increase public awareness of the U.S. prescription drug abuse epidemic, and to support private-sector efforts to address the problem.
CLAAD is a national coalition of health care providers, law enforcement, community organizations, and businesses working together to reduce prescription drug abuse while optimizing patient care. CLAAD's National Prescription Drug Abuse Prevention Strategy, which has earned the endorsements of 30 non-profit health and safety organizations, identifies the adoption of new technologies as an essential component of prescription drug abuse prevention policy.
Michael Barnes, spokesman for CLAAD, stated, "The private sector is developing some fascinating technologies to address prescription drug abuse. The 'Top 5 Technologies' contest will help health care providers, policy makers, and most importantly, the public, become aware of them."
San Diego-based Millennium Laboratories, CLAAD's exclusive representative of the medication monitoring and drug detection industry, is co-sponsoring the "Top 5 Technologies" contest. Founded in 2007, Millennium provides medication monitoring, drug detection and pharmacogenetic testing services backed by expert clinical guidance.
"Our company is proud to be teaming up with CLAAD to identify top technologies that are helping to mitigate the misuse and abuse of prescription drugs," said Howard Appel, President of Millennium Laboratories. "Continued development of innovative tools will both advance patient care and help address the epidemic of prescription drug abuse. We look forward to recognizing those companies joining Millennium in this critically important effort."
Contest submissions are due before 5:01 p.m. Eastern Time on October 5, 2012. The "Top 5 Technologies To Reduce Prescription Drug Abuse" will be selected by a panel of five U.S. consumers who are not affiliated with CLAAD, its coalition members, or contest entrants. Winners will be announced on November 27, 2012, at the National Prescription Drug Abuse Prevention Policy Consensus Meeting in Washington, DC.
For more information on the "Top 5 Technologies To Reduce Prescription Drug Abuse" contest, visit www.claad.org.
About the Center for Lawful Access and Abuse Deterrence
The tax-exempt, not-for-profit Center for Lawful Access and Abuse Deterrence (CLAAD) coordinates a comprehensive national effort to prevent the diversion, misuse, and abuse of prescription medications while ensuring optimal medical care for patients in need. CLAAD enables health professionals, law enforcement, businesses, and government, among many other entities, to share resources and work together to reduce prescription drug abuse, addiction, and overdoses. CLAAD’s National Prescription Drug Abuse Prevention Strategy has been endorsed by 30 non-profit organizations. Its fifth annual National Prescription Drug Abuse Prevention Policy Consensus Meeting will take place on November 27, 2012, in Washington, DC. More information on CLAAD may be accessed online at www.claad.org.
About Millennium Laboratories
Millennium Laboratories is the leading research-based, clinical diagnostic company dedicated to improving the lives of people with chronic pain and/or addiction. The company provides healthcare professionals with medication monitoring, drug detection and pharmacogenetic testing services to personalize treatment plans to improve clinical outcomes and patient safety. Millennium's commitment to advancing the science of pain management includes a strong focus on industry research, education and advocacy. Through its association with the Millennium Research Institute, a nonprofit national research center, it has gained respect as a leader in providing healthcare professionals with education and research to advance the assessment and management of chronic pain.
For more information contact:
Paul Scott O’Neill, Policy Advisor
This e-mail address is being protected from spambots. You need JavaScript enabled to view it
(202) 599-8435, ext. 701
